Profile data is unavailable for this security.
About the company
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
- Revenue in USD (TTM)1.88m
- Net income in USD-15.57m
- Incorporated2014
- Employees35.00
- LocationBeyondspring Inc100 Campus DriveWest Side, 4Th Floor, Suite 410FLORHAM PARK 07932United StatesUSA
- Phone+1 (646) 528-4184
- Websitehttps://www.beyondspringpharma.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allovir Inc | 0.00 | -100.20m | 65.86m | 112.00 | -- | 0.5433 | -- | -- | -0.8755 | -0.8755 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -54.04 | -52.85 | -59.58 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Agenus Inc | 160.43m | -227.86m | 67.09m | 389.00 | -- | -- | -- | 0.4182 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Bioatla Inc | 11.00m | -81.82m | 67.20m | 65.00 | -- | 2.93 | -- | 6.11 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| CytomX Therapeutics Inc | 126.62m | 13.83m | 67.81m | 120.00 | 5.17 | -- | 4.33 | 0.5356 | 0.1675 | 0.1675 | 1.52 | -0.2998 | 0.7031 | -- | 43.88 | 1,055,142.00 | 7.68 | -21.53 | 29.38 | -32.32 | -- | -- | 10.92 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 68.04m | 89.00 | -- | 0.4973 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Metagenomi Inc | 55.08m | -73.95m | 68.18m | 207.00 | -- | 0.2664 | -- | 1.24 | -2.51 | -2.51 | 1.67 | 6.83 | 0.1479 | -- | 24.41 | 233,389.80 | -19.86 | -- | -23.47 | -- | -- | -- | -134.27 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 69.59m | -- | 4.03 | 0.1408 | 35.99 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 70.12m | 35.00 | -- | -- | -- | 37.38 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Vistagen Therapeutics Inc | 875.70k | -39.57m | 70.44m | 45.00 | -- | 0.7362 | -- | 80.44 | -1.30 | -1.30 | 0.0289 | 3.44 | 0.0121 | -- | -- | 22,453.85 | -54.69 | -62.84 | -58.94 | -68.03 | -- | -- | -4,518.12 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Aligos Therapeutics Inc | 6.00m | -76.95m | 71.00m | 68.00 | -- | 1.36 | -- | 11.84 | -18.70 | -18.70 | 1.12 | 14.53 | 0.0688 | -- | -- | 90,863.63 | -88.31 | -51.20 | -117.62 | -59.73 | -- | -- | -1,283.19 | -1,399.21 | -- | -- | 0.004 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 73.52m | 12.00 | -- | 8.95 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| VolitionRX Ltd | 1.29m | -29.87m | 74.69m | 110.00 | -- | -- | -- | 58.09 | -0.3623 | -0.3623 | 0.0155 | -0.2328 | 0.0837 | -- | 7.41 | 11,689.36 | -196.61 | -111.92 | -- | -196.20 | -- | -- | -2,348.71 | -10,793.31 | -- | -104.15 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Ovid Therapeutics Inc | 631.56k | -32.50m | 75.23m | 25.00 | -- | 0.9866 | -- | 119.12 | -0.4598 | -0.4598 | 0.0089 | 1.07 | 0.0056 | -- | -- | 15,789.00 | -28.55 | -20.78 | -31.34 | -23.27 | -- | -- | -5,146.15 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 75.31m | 143.00 | -- | 0.356 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 75.34m | 51.00 | -- | 0.936 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Beyondspring Inc's reporting currency: US Dollar USD
1.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2024 | 250.00k | 0.62% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 116.69k | 0.29% |
| BlackRock Financial Management, Inc.as of 30 Sep 2024 | 87.44k | 0.22% |
| Tanaka Capital Management, Inc.as of 30 Sep 2024 | 29.47k | 0.07% |
| Geode Capital Management LLCas of 30 Sep 2024 | 24.37k | 0.06% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 16.71k | 0.04% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 11.70k | 0.03% |
| XTX Markets LLCas of 30 Sep 2024 | 10.33k | 0.03% |
| BlackRock Investment Management LLCas of 30 Sep 2024 | 10.05k | 0.03% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 2024 | 8.00k | 0.02% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
